Member Info for jonbhoy

Maybe in the next RNs

Seem to be an awful lot of people fixated with next placing give it a rest it will happen when it happens

I indeed they are in negotiations with a number of interested parties I Would hope they have provided more information to them because what they have released in all RNS's has been very vague and I wouldn't think companies would buy into it on this evidence or lack of said.

sorry that RNS was on the 27th May 15.

I Have been here long before the consolidation and remember it going all the way up to78p before crashing on that infamous RNS on 15th may 2015 The board of ValiRx notes the recent increase in the Company's share price and confirms that it is not aware of any reason that would lead to such a movement. Since then the SP has been in permanent decline

bod short sightedness has cost them in the long run

Brexit will be complete before this reaches 27p

ALAMEDA, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVuTM, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer diagnosis. As outlined in OncoCyte's announcement, the R&D validation study demonstrated a sensitivity of 90% (95% CI 82%-95%) and specificity of 75% (95% CI 68%-81%) of DetermaVuTM on a prospectively collected cohort of 250 patient blood samples that were blinded to laboratory operators. A 95% confidence interval (CI) suggests that there is a 95% chance that test performance will be within the stated range.

According to OncoCyte, these results indicate that DetermaVuTM significantly exceeds the critical parameters necessary for use in lung cancer diagnosis and clearly outperforms reported results from competitors' tests and other clinical models. OncoCyte believes that the potential U.S. market opportunity for DetermaVuTM is $4.7 billion. OncoCyte intends to make DetermaVuTM commercially available in the second half of 2019.

when are you going to beak out?

So dracula1 surely if a deal had been done they would have to release that information to the market.

Where will we Finnish today red or blue

Time to take a couple of valium this share will be the death of me up down up down down further.

Naw let’s get news out there as soon as possible

Obelix I sincerely hope so

the reason they are susceptable to abuse is that every time they release an RNs they leave more questions than answers it's as if they are hiding something from the shareholders.

Uncanny if what you said is true name the two directors who find it so funny they can laugh at the shareholders, yes they invested a joke amount of money to buy shares to add to the millions of shares they awarded themselves in options. since you seem to have their ears tell them we could do with more frequent updates.

Please don’t use imminent here as that could mean years going with history of valirx

Didn't realise we had a psychologist on here Kane, I will change my attitude when the bod give me something to cheer about. After 8 years here I will admit that I have become rather disillusioned with the whole attitude of the bod and their efforts to convince the market they have something worth investing in. I think they need help to realise making deals is not their forte.

Why so we can endure more misery

still don't see your trade but when did the SP creep up to 0.85p